tbuckley/cabot-search huggingface dataset:
AUTHOR'S REPLY
Authors: K. Wernecke, W. Bocker
Journal: Thorax (1991)

Percutaneous biopsy of mediastinal tumours under sonographic guidance In his editorial (March 1991;46:157-9) Dr K Wernecke states that sarcomas and other rare primary mediastinal tumours cannot be diag- nosed accurately by percutaneous biopsy even on the basis of large tissue cylinders.I would beg to disagree with him on this issue.Large cylinders of tissue obtained with wide bore needles can be sufficient for diagnosis even of these rare lesions.There have been great advances in the application of immunocytochemical markers to aid in the diagnosis of soft tissue tumours.'In addition, germ cell tumours can be accurately typed by means of several markers, such as human chorionic gonadotrophin, a fetoprotein, and placental aLkaline phosphatase.'Use of these markers can help the pathologist to come to a firm diagnosis even with formalin fixed material.Several sections can be obtained from these cylinders of tissue and the appropriate antibodies applied.We have recently been able to obtain sufficient tissue cylinders with the biopty gun needle (Radioplast, Sweden) from lesions in the peripheral lung to give a correct diagnosis in most cases, using both light microscopy and immuno- cytochemistry.'
Myelokathexis: normalization of neutrophil counts and morphology by GM-CSF
Authors: M. Wetzler
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Psychiatric aspects of organ transplantation
Authors: R. M. House
Journal: JAMA (1988)

DURING the past 30 years, organ transplantation has moved from being an experimental procedure to an accepted treatment for several disorders. This review discusses the most common psychiatric complications as well as psychological benefits that children, adolescents, and adult transplantation patients and their families experience. Preoperative psychiatric evaluation; psychiatric aspects of living, related, and brain-dead donors; and the support provided by the transplantation unit staff are also discussed. During the early 1950s, Hume<sup>1</sup>performed several cadaveric renal transplantations, but it was not until 1954, when Murray and colleagues<sup>2,3</sup>successfully transplanted a kidney from one identical twin brother to the other that long-term success in transplantation began to be achieved. In the 30 years since that pioneering work, long-term survival has significantly increased. This has been largely due to the increased experience of surgeons, refinement of surgical technique, improvements in tissue typing and matching, more careful selection of candidates,
Monotony
Authors: Lester S. King
Journal: JAMA (1967)

Sounds, too often repeated, no longer impress themselves on consciousness. The counting of imaginary sheep... one after the other... is a remedy for insomnia. And monotonous sentences, sufficiently repeated, can wear down the strongest resolution to study, the best intentions to learn. We react to monotonous repetition by simply withdrawing attention. Sentences may have impeccable clarity, complete objectivity, exquisite precision, and yet completely fail to hold the attention. Writing aims to communicate, but if it does not hold the attention, it fails of its purpose and might as well not have been written. Unfortunately, monotony often exerts its deadly effect without either the author or the reader having any awareness of the fault. Yet the fault is quite readily corrected, if only we are aware of it. Monotony can take several forms. I would consider, primarily, monotony in regard to sentence length and sentence structure. While the length of the
Abstracts
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Renal Function and Hydrogen-Ion Excretion After Open Intracardiac Surgery and Whole-Body Perfusion
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1715: <i>Sox2</i> is required for tumor initiation and maintenance in small cell lung cancer
Authors: Ellen Voigt, Ethan Thompson, Hannah Wollenzien, Madeline Vande Kamp, Michael S. Kareta
Journal: Cancer Research (2019)

Abstract Some cancer prognoses have been radically improved in recent years, but little headway has been made with others. One of these diseases, small cell lung cancer (SCLC,) has a five-year survival rate of less than 7% and a standard of care that has been essentially unchanged for forty years. One promising avenue to improve SCLC outcomes is to understand the cancer’s underlying genetic alterations that drive its formation and growth. One primary driver of SCLC, is the loss of Rb gene function, one of the most common occurrences in human cancers. Normally Rb promotes differentiation by regulating lineage specific transcription factors concurrent with repression of the pluripotency factors such as Sox2. However, there is evidence that when certain tissues lose Rb, Sox2 becomes upregulated and promotes oncogenesis. To understand the contribution of Sox2 to SCLC, we have utilized a genetically engineered mouse model for SCLC to determine the consequence of Sox2 on SCLC tumor initiation and growth. We observe that Sox2 is indeed required for SCLC. Further elucidation of the Sox2 network in SCLC could identify candidates for future targeted therapies in this devastating disease. Citation Format: Ellen Voigt, Ethan Thompson, Hannah Wollenzien, Madeline Vande Kamp, Michael S. Kareta. Sox2 is required for tumor initiation and maintenance in small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1715.
Phosphorus Magnetic Resonance Spectroscopy In Nutritional Research
Authors: Z Argov
Journal: Annual Review of Nutrition (1991)

Phosphorus Magnetic Resonance Spectroscopy in Nutritional Research, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/nutr/11/1/annurev.nu.11.070191.002313-1.gif
ASSOCIATION NEWS.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physiologic Assessment of Fetal Compromise: Biomarkers of Toxic Exposure
Authors: Lawrence D. Longo
Journal: Environmental Health Perspectives (1987)

Understanding the physiologic and endocrinologic basis of fetal development is a major goal of perinatal biology. During the past decade a number of technological developments have allowed more precise evaluation of the fetus in utero and diagnosis of abnormalities. Despite these methodological achievements, however, there are no specific biological markers currently available to indicate that exposure to a given xenobiotic is associated with a cellular, subcellular, or pharmacodynamic event. This paper evaluates the following issues: What are some of the unique physiologic and endocrinologic features of the fetal milieu intérieur? What problems are peculiar to fetal assessment? Of what value are techniques such as ultrasonography, amniocentesis, chorionic villus sampling, fetoscopy, and fetal blood and tissue sampling for obtaining appropriate biomarkers? What are some examples of validated biomarkers and their applicability? What promising biomarkers are on the horizon? What are some of the promising techniques such as the evaluation of fetal body movements, breathing activity, electronic heart rate monitoring, and nuclear magnetic resonance? How may molecular probes be of value as biological markers of fetal compromise? What are some of the major research gaps and needs, and how should research priorities be set? Some of these topics are addressed. Moreover, the more general role(s) that various diagnostic methods and biological markers can have in an understanding of the regulation of fetal growth and differentiation and the role of xenobiotics in affecting the normal course of events are discussed.
Transplantation
Authors: Kenneth L. Brayman, Karen V. Knight, Kelly Near
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Association Notices: Trainees subcommittee (GMSC)
Journal: BMJ (1979)

per head as the bottom seven.The disproportion is even greater on the higher awards committees. DiscussionChanges appear few and trivial.More information should emerge from the computer and, for example, the distribution of awards and advisory committee places among women consultants may become known.But, judging by the last five years, there will be little change.Reducing secrecy is part of the new consultants' contract package.This is possibly one of its least contentious items and could be implemented immediately.At present, secrecy remains in full force.Committee chairmen have hinted that the successful specialties are more meritorious, on average, than others like psychiatry and anaesthetics.6This is enshrined in the unequal quota
Authors' response
Authors: Anna Rich, David Baldwin, Richard Hubbard
Journal: Thorax (2012)

Beckett and Woolhouse have investigated the inequality in access to surgery for individuals with non-small cell lung cancer (NSCLC) in England. 1 2 They have used the number of patients entered into the National Lung Cancer Audit (NLCA) as a surrogate marker for the 'specialist' qualities of the multi-disciplinary team (MDT) and concluded that this marker does not influence surgical resection rate or survival.An MDT with a high number of patients may reflect a high level of experience, but this may not be the case for every MDT.It would be helpful to see the actual numbers of patients per MDT in each quintile and the raw data for survival.Only the largest of MDTs may link to specialist qualities.MDTs reviewing a large number of patients, but outside the top quintile, may reflect those that are under-resourced and struggling to cope.Other factors that may influence the outcomes of individuals with lung cancer in England may be: access to positron emission tomography scanning, cardiovascular assessment, lung function testing and on-site intensive treatment unit beds.Further research looking at the composition of the MDT, and also the exact nature of investigative and 'support' facilities available at every NHS Trust is needed.
CONSTITUTIONAL INADEQUACY
Authors: Jacob Lichstein
Journal: JAMA (1942)

<h3>To the Editor:—</h3> Dr. Walter C. Alvarez in his discussion of constitutional inadequacy inThe Journal, July 4, has rendered a distinct service in emphasizing the importance of this problem. It is no exaggeration to state that 30 to 40 per cent of patients who apply for treatment to the general practitioner or the medical consultant fall into the category of the "constitutionally inadequate." Yet if one peruses the medical literature year in and year out it is apparent that the attention paid to them is inadequate. Dr. Alvarez's continued interest in and occupation with this problem and his insistence that we recognize these patients promptly and so save useless time and money and, in many instances, futile surgery is a notable exception to this lack of interest. However one may agree with him as to the inherent incurability of the disease and the presence of a constitutional weakness of
ABCG2 and TOP-1 mRNA expression as predictive biomarkers for adjuvant FOLFIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial.
Authors: Nils Brunner, Jan Stenvang, Eva Budinska, Sune Boris Nygaard
Journal: Journal of Clinical Oncology (2017)

11594 Background: FOLFIRI as adjuvant treatment in primary colon cancer was previously tested in two pivotal prospective randomized clinical trials (PETACC-3 and CALGB 89803), both of which failed to demonstrate significant beneficial effects when adding irinotecan to 5FU. As a consequence, FOLFIRI is presently not used as adjuvant treatment for colon cancer. Methods: The study included 580 patients with mRNA expression data performed on tumor samples (FFPE) from stage III colon cancer patients enrolled in the PETACC-3 study, which randomized the patients to 5FU plus Leucovorin +/- irinotecan. Primary end-points were recurrence-free survival (RFS) and overall survival (OS). Median ABCG2 and the 75 percentile TOP-1 mRNA expression data were used to allocate the patients into one of two groups: One with high ABCG2 expression (above median) and low TOP-1 expression (below 75 percentile) (n = 167) and another group including all other combinations of these two genes. Kaplan Meier curves and Cox proportional hazards model were used to visualize differences between groups and calculate p-values (log-rank test). Results: The survival statistics showed a significant difference for both RFS (HR: 0.63 (0.44-0.92); p = 0.017) and OS (HR: 0.6 (0.39-0.93); p = 0.021) between the two groups when the patients received FOLFIRI. In contrast, no significant differences were observed between the groups when patients received 5FU and Leucovorin alone (p-values: RFS: 0.58; OS: 0.75). Conclusions: We here show that the combination of two independent gene expression abundance with a strong association to irinotecan treatment (high ABCG2 drug efflux pump and low TOP-1, the latter being the target for irinotecan) identified a group of stage III colon cancer patients who will not benefit from FOLFIRI adjuvant treatment while patients with other combinations of expression of these two genes appear to significantly benefit from adjuvant FOLFIRI treatment. The lack of a similar effect in patients receiving treatment with 5FU and Leucovorin only, points to a predictive value of ABCG2 and TOP-1 measurements.
Treatment of Iron Deficiency Anemia-Ineffective Iron Medication
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Penicillin
Authors: Robert G. Petersdorf
Journal: JAMA (1969)

Except for the sulfonamides, penicillin is the oldest antibacterial agent available, has been in general clinical use for nearly a quarter of a century, and has been administered to several hundred million people. However, since its inception, many antimicrobial drugs with the same or similar antibacterial spectrum have been discovered, raising the question as to whether other drugs might be superior to penicillin. In the minds of some, this question has been reinforced by the recent decision of the NAS-NRC Drug Efficacy Review Panel that penicillin-sulfonamide and penicillin-streptomycin combinations are not efficacious.<sup>1</sup> Penicillin is uniformly bactericidal in low concentrations against group A streptococci, pneumococci, nonpenicillinase-producing staphylococci, meningococci, and, in somewhat higher concentrations, gonococci, and certain enteric bacteria. It is also a potent treponemocidal agent. Translated into the clinical setting, this means that penicillin is highly effective in most cases of exudative pharyngitis, otitis media, pneumonia, meningitis (except for infants
KEYNOTE-122: Phase 2 study of pembrolizumab versus standard-of-care chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal carcinoma
Authors: Q.S. Ng, A. Spreafico, V. Lee, R.K.C. Ngan, K.F. To, M.-J. Ahn, R.-L. Hong, J- C. Lin, R.F. Swaby, A.T.C. Chan
Journal: Annals of Oncology (2016)